Maxim Group Forecasts Strong Price Appreciation for OS Therapies (NYSE:OSTX) Stock

Posted by Oscar Bower on Jan 19th, 2025

OS Therapies (NYSE:OSTX – Free Report) had its price target hoisted by Maxim Group from $8.00 to $15.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a research note on Wednesday.

View Our Latest Stock Analysis on OSTX

OS Therapies Price Performance

NYSE OSTX opened at $2.95 on Thursday. The company has a 50-day moving average of $3.32. OS Therapies has a twelve month low of $1.58 and a twelve month high of $7.00.

Insider Activity at OS Therapies

In related news, major shareholder Shalom Auerbach sold 16,720 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the transaction, the insider now owns 2,531,211 shares of the company’s stock, valued at $17,060,362.14. This represents a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in OS Therapies Inc (NYSE:OSTX – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

(Get Free Report)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.